Cargando…

Tyrosine Kinase Inhibitor discontinuation in Chronic Myeloid Leukemia: eligibility criteria and predictors of success

TKI discontinuation proved to be safe and feasible in patients with CML with deep and durable molecular responses, introducing an additional treatment goal for these patients beyond overall survival. However, treatment interruption is a safe procedure only with appropriate patient selection and moni...

Descripción completa

Detalles Bibliográficos
Autores principales:	Inzoli, Elena, Aroldi, Andrea, Piazza, Rocco, Gambacorti‐Passerini, Carlo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Inc. 2022
Materias:	Critical Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9546318/ https://www.ncbi.nlm.nih.gov/pubmed/35384030 http://dx.doi.org/10.1002/ajh.26556

Ejemplares similares

Caution in using second generation tyrosine kinase inhibitor, especially for first line therapy of chronic myeloid leukemia
por: Gambacorti‐Passerini, Carlo, et al.
Publicado: (2022)

Molecular Pathogenesis of BCR-ABL-Negative Atypical Chronic Myeloid Leukemia
por: Fontana, Diletta, et al.
Publicado: (2021)

P667: RISK OF PROGRESSION IN CHRONIC PHASE-CHRONIC MYELOID LEUKEMIA PATIENTS ELIGIBLE FOR TYROSINE KINASE INHIBITOR DISCONTINUATION: FINAL ANALYSIS OF THE TFR-PRO STUDY
por: Paolo Maria Zambrotta, Giovanni, et al.
Publicado: (2023)

Tyrosine kinase inhibitor interruptions, discontinuations and switching in patients with chronic‐phase chronic myeloid leukemia in routine clinical practice: SIMPLICITY
por: Hehlmann, Rüdiger, et al.
Publicado: (2018)

Predictive indicators of successful tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia
por: Stuckey, Ruth, et al.
Publicado: (2020)

Clinical Benefit of Lenzilumab in Cases of Coronavirus Disease 2019
por: Aroldi, Andrea, et al.
Publicado: (2021)

DNA Damage Response (DDR) Is Associated With Treatment-free Remission in Chronic Myeloid Leukemia Patients
por: Malighetti, Federica, et al.
Publicado: (2023)

P1056: NEXT GENERATION SEQUENCING IDENTIFIES SUBGROUPS OF PATIENTS WITH TRIPLE NEGATIVE/ PRIMARY THROMBOCYTOSIS WITH DIFFERENT CLINICAL OUTCOMES
por: Sangiorgio, Valentina, et al.
Publicado: (2023)

Observational study of chronic myeloid leukemia Italian patients who discontinued tyrosine kinase inhibitors in clinical practice
por: Fava, Carmen, et al.
Publicado: (2019)

Transfusion of blood products derived from SARS-CoV-2+ donors to patients with hematological malignancies
por: Gambacorti-Passerini, Carlo, et al.
Publicado: (2021)

Patient-Initiated Discontinuation of Tyrosine Kinase Inhibitor for Chronic Myeloid Leukemia
por: Langabeer, Stephen E., et al.
Publicado: (2020)

Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: when and for whom?
por: Atallah, Ehab, et al.
Publicado: (2020)

A monocentric analysis of the long-term safety and efficacy of crizotinib in relapsed/refractory ALK(+) lymphomas
por: Rindone, Giovanni, et al.
Publicado: (2022)

Brazilian chronic myeloid leukemia working group recommendations for discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia in clinical practice
por: Boquimpani, Carla, et al.
Publicado: (2022)

Long-term and low-dose of busulfan is a safe and effective second-line treatment in elderly patients with essential thrombocythemia resistant or intolerant to hydroxyurea
por: Renso, Rossella, et al.
Publicado: (2018)

Tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia: a single-institution experience
por: Chamoun, Kamal, et al.
Publicado: (2019)

Integrated Genomic, Functional, and Prognostic Characterization of Atypical Chronic Myeloid Leukemia
por: Fontana, Diletta, et al.
Publicado: (2020)

Practical management of toxicities associated with bosutinib in patients with Philadelphia chromosome-positive chronic myeloid leukemia
por: Khoury, H J, et al.
Publicado: (2018)

CHARACTERISTICS AND OUTCOMES OF COVID-19 PATIENTS MEETING VENO-VENO ECMO ELIGIBILITY CRITERIA RECEIVING ECMO VS CONVENTIONAL THERAPY ALONE
por: SIPSEY, LYNN, et al.
Publicado: (2022)

Mitochondrial Hyperactivation and Enhanced ROS Production are Involved in Toxicity Induced by Oncogenic Kinases Over-Signaling
por: Ceccon, Monica, et al.
Publicado: (2018)

Patient- and physician-reported pain after tyrosine kinase inhibitor discontinuation among patients with chronic myeloid leukemia
por: Flynn, Kathryn E., et al.
Publicado: (2022)

A Retrospective Analysis about Frequency of Monitoring in Italian Chronic Myeloid Leukemia Patients after Discontinuation
por: Dragani, Matteo, et al.
Publicado: (2020)

An Imatinib–non‐responsive patient with an ABL Leu387Trp mutation achieves cytogenetic and molecular response under bosutinib: Case report and biological characterization
por: Crespiatico, Ilaria, et al.
Publicado: (2019)

Relationship between molecular response and quality of life with bosutinib or imatinib for chronic myeloid leukemia
por: Brümmendorf, Tim H., et al.
Publicado: (2020)

Interferon-α may help prevent molecular relapse of chronic myeloid leukemia after the discontinuation of tyrosine kinase inhibitors
por: Jun, Kong, et al.
Publicado: (2021)

P677: THE FACTORS OF LATE MOLECULAR RELAPSES AFTER TYROSINE KINASE INHIBITORS DISCONTINUATION IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA
por: Petrova, Anna, et al.
Publicado: (2023)

Discontinuation of Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia: a Review of the Biological Factors Associated with Treatment-Free Remission
por: Stuckey, Ruth, et al.
Publicado: (2022)

Discontinuation of tyrosine kinase inhibitors based on BCR-ABL1 monitoring by digital droplet PCR in pediatric chronic myeloid leukemia
por: Kim, Yeojae, et al.
Publicado: (2022)

Cross-intolerance with bosutinib after prior tyrosine kinase inhibitors for Philadelphia chromosome-positive leukemia: long-term analysis of a phase I/II study
por: Cortes, Jorge E., et al.
Publicado: (2023)

FusionAnalyser: a new graphical, event-driven tool for fusion rearrangements discovery
por: Piazza, Rocco, et al.
Publicado: (2012)

NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922
por: Mologni, Luca, et al.
Publicado: (2015)

VERSO: A comprehensive framework for the inference of robust phylogenies and the quantification of intra-host genomic diversity of viral samples
por: Ramazzotti, Daniele, et al.
Publicado: (2021)

Tyrosine Kinase Inhibitor Therapy Discontinuation for Patients with Chronic Myeloid Leukaemia in Clinical Practice
por: Clark, Richard E.
Publicado: (2019)

The criteria of eligibility to the extracorporeal treatment
por: Zangrillo, A
Publicado: (2012)

Management of adverse events associated with bosutinib treatment of chronic-phase chronic myeloid leukemia: expert panel review
por: Cortes, Jorge E., et al.
Publicado: (2018)

Predictors of successful discontinuation of antipsychotics and antidepressants
por: Lincoln, Tania M., et al.
Publicado: (2023)

Successful treatment of chronic myeloid leukemia with tyrosine kinase inhibitors goes beyond access to drugs
por: Conchon, Monika
Publicado: (2013)

Downregulation of Plasma miR-215 in Chronic Myeloid Leukemia Patients with Successful Discontinuation of Imatinib
por: Ohyashiki, Kazuma, et al.
Publicado: (2016)

Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia
por: Ilander, M, et al.
Publicado: (2017)

De‐escalation or discontinuation of tyrosine kinase inhibitor in patients with chronic myeloid leukemia: A multicentral, open‐label, prospective trial in China
por: Luo, Jie, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_dts9ac3agi9d296du28utbnhgm